UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported): May 11, 2005
BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)
Delaware | 1-1136 | 22-079-0350 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification Number) |
345 Park Avenue
New York, NY, 10154
(Address of Principal Executive Office)
Registrants telephone number, including area code: (212) 546-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On May 11, 2005, Bristol-Myers Squibb Company issued a press release announcing it had completed the sale of its Oncology Therapeutics Network (OTN) distribution business to One Equity Partners LLC. A copy of the press release is attached to this report as Exhibit 99.1.
Item 9.01 Financial Statement and Exhibits
(c) Exhibits
99.1 Press release, dated May 11, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Bristol-Myers Squibb Company | ||||
Date: May 12, 2005 | ||||
By: | /s/ Sandra Leung | |||
Name: | Sandra Leung | |||
Title: | Secretary |
EXHIBIT INDEX
Exhibit No. |
Description | |
99.1 | Press Release, dated May 11, 2005 |